Humana (NYSE:HUM) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Humana (NYSE:HUM) posted its quarterly earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10, Zacks reports. Humana had a return on equity of 13.20% and a net margin of 1.18%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Price Performance

NYSE:HUM opened at $259.93 on Thursday. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The firm has a market capitalization of $31.30 billion, a price-to-earnings ratio of 23.02, a P/E/G ratio of 2.11 and a beta of 0.56. The stock’s 50 day moving average price is $273.00 and its two-hundred day moving average price is $295.72. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Morgan Stanley cut their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Barclays increased their price target on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 22nd. Piper Sandler boosted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $292.26.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.